Nicox announced the transfer its european and international commercial operations, for a value of up to €26 million, to a newly-founded private company focused on the commercialisation of a portfolio of ophthalmic products in Europe.  The new company will combine Nicox’s existing commercial infrastructure and portfolio with the financial resources and capabilities of GHO Capital.  Under the terms of the transaction, Nicox will assign related product and trademark rights to the new company. All rights to Nicox’s unencumbered R&D pipeline programs, including AC-170, and rights under the latanoprostene bunod agreement with Bausch + Lomb remain entirely with Nicox.